CATT Trial (Comparison of Age-Related Macular Degeneration Treatments Trials)

CATT 1 (1-year results) - CATT Research Group, NEJM 2011;364:1897-1908

• Primary outcome: mean change in visual acuity (VA) at 1 year.
• Ranibizumab-monthly and bevacizumab-monthly produced nearly identical VA gains (about +8 letters each), meeting non-inferiority criteria.
• Ranibizumab given PRN was equivalent to ranibizumab monthly.
• Bevacizumab-PRN gains were slightly smaller and, by the strictest statistical margin, did not conclusively meet non-inferiority versus ranibizumab-monthly, though the clinical difference was small.
• Anatomic outcomes (retinal thickness on OCT, fluid resolution) showed slightly more residual fluid with bevacizumab, without translating into a meaningful VA difference.
• Ocular serious adverse events (endophthalmitis, uveitis) were low and similar between drugs.
• Bottom line at 1 year: bevacizumab was essentially non-inferior to ranibizumab for VA outcomes, supporting its continued off-label use given the large cost difference - "The Comparison of Age-Related Macular Degeneration Treatments Trial (CATT) study demonstrated the noninferiority of bevacizumab as compared to ranibizumab at 1 year." (The Wills Eye Manual, p. 841)

CATT 2 (2-year results) - Martin DF et al., Ophthalmology 2012

• Patients originally assigned to monthly dosing were re-randomized at year 1 to continue monthly or switch to PRN, allowing assessment of drug effect and dosing-schedule effect independently over 2 years.
• VA outcomes: mean VA gains at 2 years remained similar between ranibizumab and bevacizumab across dosing regimens - drug choice did not significantly affect visual outcome.
• Switching to PRN: eyes switched from monthly to PRN dosing lost a small amount of vision compared with continuing monthly therapy (a few letters), and the "switch" arms did not always meet non-inferiority versus continued monthly dosing, suggesting monthly dosing gives slightly more durable benefit than PRN, at the cost of more injections.
• Geographic atrophy: by year 2, incidence was higher with ranibizumab than bevacizumab (21% vs 17%, p=0.02) and higher with monthly than PRN dosing - raising a hypothesis (not proven causally) that higher VEGF suppression might promote atrophy, though this was not replicated in the similarly designed IVAN trial (28% vs 31%, p=0.46).
• Systemic safety: the rate of systemic serious adverse events (mostly hospitalizations) was higher with bevacizumab than ranibizumab at 2 years (about 24% vs 19%, p=0.04), but there was no consistent pattern implicating any specific organ system, and no significant difference in arteriothrombotic events, myocardial infarction, stroke, or death. This finding has been debated and was not confirmed as causal in later meta-analyses (Cochrane review, Moja et al. 2014, PMID 25220133), which found no significant difference in mortality or arteriothrombotic events between the two drugs across pooled trials, though it flagged a possible signal for increased "any systemic serious adverse event" with bevacizumab, driven mainly by gastrointestinal disorders.

Clinical relevance

• Related trials reached similar conclusions: IVAN (UK) found equivalent visual outcomes between the two drugs, and the geographic atrophy signal was not replicated. Both CATT and IVAN together underpin the widespread off-label use of bevacizumab as a cost-effective alternative to ranibizumab in many health systems (Kanski's Clinical Ophthalmology, p. 613).
• A later CATT Follow-up Study (~5 years) found that the VA gains achieved during the 2-year trial were not sustained long-term once patients returned to routine, less-standardized community care, underscoring that ongoing anti-VEGF treatment (not just initial response) drives long-term visual outcomes.

Intraocular Lenses (IOLs) - PG Ophthalmology Notes

Topic Breakdown

1. Introduction & Historical Development - Ridley's first IOL, evolution of materials and designs
2. Classification of IOLs - by material (PMMA/rigid vs foldable: acrylic hydrophobic/hydrophilic, silicone, collamer), by design (haptic type - loop vs plate, one-piece vs three-piece), by location (ACIOL, PCIOL, iris-fixated, scleral-fixated), by optic function (monofocal, multifocal, toric, EDOF, accommodating)
3. Optics of IOLs - power calculation formulas (SRK/T, Holladay 1/2, Hoffer Q, Barrett Universal II, Olsen), biometry (optical vs immersion vs IOL Master/swept-source OCT biometry), effective lens position, spherical aberration and asphericity, chromatic aberration
4. Types of IOLs in detail - monofocal (spherical vs aspheric), multifocal (refractive vs diffractive), trifocal, extended depth of focus (EDOF), toric, accommodating, phakic IOLs (ICL, iris-fixated phakic lenses)
5. Latest/Newer IOLs - Light Adjustable Lens (LAL), small-aperture IOLs (IC-8), new-generation trifocal/EDOF combos (PanOptix, Symfony, FineVision), accommodating IOLs (Crystalens successors), continuous-focus IOLs, presbyopia-correcting IOL innovations
6. IOL-related complications - posterior capsular opacification (PCO), dysphotopsia (positive/negative), IOL calcification, IOL malposition/dislocation/subluxation, uveitis-glaucoma-hyphema (UGH) syndrome, toxic anterior segment syndrome
7. Special features - blue light/UV filters, square-edge optic design, heparin-surface-modified IOLs
8. IOL selection in special situations - pediatric cataract, post-refractive surgery eyes, uveitic eyes, silicone oil-filled eyes

Brief Overview

Intraocular Lenses (IOLs) - Detailed PG Notes

1. Introduction & Historical Development

• Sir Harold Ridley (St Thomas' Hospital, London) implanted the first IOL in 1949, inspired by observing that RAF pilots tolerated PMMA (Perspex) canopy fragments in their eyes without inflammatory reaction after WWII injuries.
• First-generation IOLs were rigid PMMA lenses placed in the posterior chamber; early designs suffered high complication rates (dislocation, UGH syndrome with early anterior chamber lenses).
• Evolution: rigid PMMA -> foldable IOLs (silicone, then acrylic) delivered through small incisions via injector -> modern square-edge, aspheric, presbyopia-correcting, and adjustable-power lenses.
• Injector-based delivery through a small (2.2-2.8 mm) incision is now standard, reducing surgically induced astigmatism and infection risk by avoiding contact between the implant and ocular surface.

2. Classification of IOLs

• Rigid: Polymethylmethacrylate (PMMA) - cannot be folded/injected, needs a 5-6 mm incision. Cheap, still used in resource-limited settings. Higher PCO rates than acrylic/silicone.
• Foldable/flexible:
  • Hydrophobic acrylic (water content <1%): higher refractive index -> thinner lens; slightly more prone to dysphotopsia; lower PCO rates.
  • Hydrophilic acrylic (hydrogel): better theoretical biocompatibility; historically associated with late calcification (largely resolved with newer manufacturing) and possibly higher PCO rates.
  • Silicone: available as loop-haptic (1- or 3-piece) or plate-haptic; very biocompatible but can develop silicone oil droplet deposition in eyes later filled with silicone oil (relevant in vitreoretinal patients) - relatively contraindicated if silicone oil tamponade is anticipated.
  • Collamer: collagen + poly-HEMA copolymer with a UV chromophore; used mainly in phakic ICLs; excellent biocompatibility.

• One-piece vs three-piece (separate haptics welded to optic - useful for sulcus fixation or when capsular support is compromised).
• Loop haptic vs plate haptic.

• Anterior chamber IOL (ACIOL): angle-supported or iris-fixated/iris-claw - used when capsular support is absent.
• Posterior chamber IOL (PCIOL): in-the-bag (standard, most physiologic) or ciliary sulcus-fixated.
• Iris-fixated (iris-claw/Artisan) and scleral-fixated (sutured or sutureless, e.g., Yamane technique, Glued IOL): for eyes lacking capsular/zonular support.
• Phakic IOLs: implanted in a phakic eye (natural lens retained) for high refractive errors - anterior chamber angle-supported, iris-fixated, or posterior chamber (ICL) types.

• Monofocal (spherical or aspheric)
• Toric (astigmatism correction)
• Multifocal - refractive or diffractive
• Trifocal
• Extended depth of focus (EDOF)
• Accommodating (pseudo-accommodative)
• Light adjustable lens (power tunable post-operatively)

3. Optics of IOLs

• Keratometry: corneal curvature/power measurement.
• Axial length (AL) measurement methods:
  • Applanation/immersion A-scan ultrasound
  • Optical (partial) coherence biometry (IOLMaster, Lenstar) - non-contact, uses coaxial partially coherent laser interference; now the standard of care for accuracy.
• Confounders of axial length measurement: poor fixation, staphyloma/irregular globe contour, silicone oil in vitreous (velocity differs from vitreous, causing errors), previous corneal refractive surgery (alters keratometry-AL relationship), dense cataract/posterior subcapsular opacity affecting signal.

• Regression-based (older): SRK, SRK II
• Theoretical/vergence formulas: SRK/T, Hoffer Q, Holladay 1 - differ mainly in how they estimate effective lens position (ELP) based on AL and keratometry.
  • Hoffer Q: best for short eyes (AL <22 mm)
  • Holladay 1: medium axial lengths
  • SRK/T: better for long/myopic eyes (AL >26 mm)
• Newer generation formulas: Holladay 2, Barrett Universal II, Olsen (ray tracing), Kane formula (AI/theoretical hybrid) - use additional variables (anterior chamber depth, lens thickness, white-to-white) for improved ELP prediction; Barrett Universal II and Kane currently show the best overall accuracy across axial length ranges in comparative studies.
• Post-refractive surgery eyes need specific methods (e.g., ASCRS post-refractive calculator, Haigis-L, Barrett True-K) because standard keratometry misestimates true corneal power after LASIK/PRK/RK.

• Spherical aberration: the natural crystalline lens has positive spherical aberration in youth but the cornea has positive aberration too; aging lens changes shift balance. Standard spherical IOLs add positive spherical aberration to the eye's total aberration, degrading contrast sensitivity, especially in low light/large pupils. Aspheric IOLs are designed with zero or negative spherical aberration to neutralize the cornea's inherent positive spherical aberration and improve contrast sensitivity and image quality, particularly in mesopic conditions.
• Chromatic aberration: difference in refractive index across wavelengths; some newer EDOF/monofocal-plus designs incorporate diffractive elements or achromatic technology to reduce this.
• Diffractive vs refractive multifocal optics: refractive designs create distinct simultaneous zones/rings of differing power on the anterior or posterior surface (pupil-size dependent); diffractive designs use concentric microscopic steps that split light into distinct foci (near/intermediate/distance) largely independent of pupil size but causing light loss/scatter (halos, reduced contrast sensitivity).
• Extended depth of focus (EDOF) optics: use a single elongated focal zone (via echelette diffractive design or small-aperture pinhole effect) rather than multiple discrete foci, aiming to smooth the defocus curve and reduce dysphotopsias compared with multifocal/trifocal lenses, at the cost of somewhat reduced near vision compared to trifocals.

4. Types of IOLs in Detail

• Implantable Collamer Lens (ICL, Visian ICL): posterior chamber, placed between iris and natural crystalline lens, supported in the ciliary sulcus; central hole (KS-AquaPORT) in modern versions permits aqueous flow, reducing pupillary block risk without need for peripheral iridotomy.
• Iris-fixated phakic IOL (Artisan/Verisyse): clipped onto mid-peripheral iris.
• Angle-supported ACIOL: largely abandoned due to higher endothelial cell loss rates.
• Requires adequate anterior chamber depth (typically ≥3.0 mm) and endothelial cell count for safety.

5. Latest IOLs and Emerging Technology

• Light Adjustable Lens (LAL, RxSight): silicone-based photosensitive lens whose power can be non-invasively fine-tuned weeks after surgery using targeted UV light exposures, allowing refractive outcome to be customized to the patient's actual healed refraction rather than pre-op calculation alone; particularly useful in post-refractive surgery eyes and premium IOL patients wanting precision.
• Small-aperture (pinhole) IOLs (e.g., IC-8): use a mini-ring with a central aperture to increase depth of focus via a pinhole effect rather than diffractive optics; useful in eyes with irregular astigmatism or mild corneal pathology since they are less dependent on regular optics.
• Newer trifocal/EDOF hybrid platforms (e.g., PanOptix, Symfony/Symfony OptiBlue, FineVision, Acrysof IQ Vivity - a non-diffractive EDOF using a proprietary "X-WAVE" wavefront-shaping technology): aim to broaden the range of clear vision while minimizing dysphotopsia compared with earlier-generation diffractive multifocals.
• Continuous/monofocal-plus lenses: subtle EDOF effect intended to give a small boost to intermediate vision while behaving almost like a monofocal for contrast sensitivity and side-effect profile.
• Accommodating IOL redesigns (dual-optic and shape-changing designs) continue to be investigated to better replicate true accommodation, though long-term efficacy remains limited compared with diffractive/EDOF options.
• Current comparative evidence (Cochrane 2024, PMID 38984608; AJO meta-analysis 2023, PMID 36736751) indicates trifocal IOLs generally provide superior near vision and greater spectacle independence than EDOF lenses, while EDOF lenses tend to produce fewer photic phenomena (glare/halo) and slightly better contrast sensitivity - the choice is individualized based on patient visual demands and tolerance for dysphotopsia.

6. IOL-Related Complications

• Posterior capsular opacification (PCO): the most common cause of delayed visual decline after cataract surgery, due to residual lens epithelial cell proliferation/migration onto the posterior capsule (pearl formation - Elschnig pearls, or fibrous). Sharp/square optic edge design significantly reduces PCO incidence versus round edges (mechanical barrier effect) but is associated with a higher rate of dysphotopsia. Hydrophilic acrylic and PMMA lenses have historically shown higher PCO rates than hydrophobic acrylic/silicone. Treatment: Nd:YAG laser posterior capsulotomy.
• Dysphotopsia:
  • Positive dysphotopsia: glare, halos, streaks, arcs, or flashes of light - related to edge design, refractive index, and reflections off the square optic edge.
  • Negative dysphotopsia: dark temporal crescent/shadow - often more troublesome and harder to treat; management options include pupil dilation (miotics avoided), reverse optic capture, piggyback IOL, or IOL exchange/repositioning in refractory cases.
• IOL malposition/subluxation/dislocation: causes include zonular weakness (pseudoexfoliation, trauma, Marfan syndrome), capsular bag phimosis/contraction, or inadequate haptic fixation. Late in-the-bag dislocation is increasingly recognized in eyes with pseudoexfoliation years after uncomplicated surgery.
• Uveitis-Glaucoma-Hyphema (UGH) syndrome: chronic mechanical irritation of iris/ciliary body by a malpositioned IOL (classically closed-loop ACIOLs or a sulcus-placed single-piece acrylic IOL not designed for sulcus fixation), producing recurrent low-grade uveitis, elevated IOP, and hyphema.
• IOL calcification: seen historically with certain hydrophilic acrylic lens models, presenting as progressive opacification requiring lens exchange.
• Toxic anterior segment syndrome (TASS): sterile postoperative inflammation from contaminants (e.g., residual detergents/enzymes on instruments), not an IOL material defect per se but relevant in the differential of postoperative inflammation after IOL implantation.
• Refractive surprise: due to biometry/formula error, altered effective lens position, or unmasked pre-existing astigmatism.

7. Special Features of Modern IOLs

• UV filters: essentially universal in modern IOLs to protect the retina from ultraviolet damage (replacing the natural crystalline lens's UV-absorbing function).
• Blue-light filtering IOLs: additional chromophore imparting a slight yellow tint (similar to the young adult natural lens) to filter high-energy visible blue light, theoretically reducing phototoxic retinal risk; associated with slightly reduced scotopic visual function in some studies, and clinical benefit remains debated.
• Sharp/square-edged optic: now the predominant design specifically to reduce PCO.
• Heparin surface-modified IOLs: reduce inflammatory cell/fibrin adhesion to the IOL surface; preferred by some surgeons in eyes with pre-existing uveitis or in pediatric cataract surgery where postoperative inflammation is expected to be higher.
• Aspheric optics: now standard in most premium and many standard monofocal lenses to reduce spherical aberration and improve contrast sensitivity.

8. IOL Selection in Special Situations

• Pediatric cataract surgery: PCO is nearly universal if the posterior capsule is retained, given the strong proliferative capacity of young lens epithelial cells - primary posterior capsulotomy with anterior vitrectomy is often combined with IOL implantation in young children. Acrylic IOLs with heparin coating are favored in children due to higher expected postoperative inflammation. IOL power calculation in children must account for ongoing eye growth (myopic shift), often intentionally under-correcting (planned hyperopic target) in very young children.
• Post-refractive surgery eyes: standard keratometry-based formulas are unreliable; use specific calculators/formulas (Haigis-L, Barrett True-K, ASCRS calculator) or, where available, the Light Adjustable Lens to correct residual refractive error postoperatively.
• Uveitic eyes: hydrophobic acrylic lenses with square edges and possibly heparin coating are preferred; multifocal/diffractive IOLs are generally avoided due to risk of reduced contrast sensitivity compounding inflammatory macular/vitreous changes.
• Eyes anticipating silicone oil tamponade (vitreoretinal surgery candidates): avoid silicone IOLs (oil droplet adherence to lens surface degrades vision); acrylic IOLs preferred.
• Absent capsular/zonular support (post-vitrectomy, trauma, pseudoexfoliation with zonulopathy, Marfan syndrome): consider iris-fixated or scleral-fixated (sutured or sutureless Yamane/glued technique) IOLs, or angle-supported ACIOL in select cases.
• High myopes/hyperopes not suited for corneal refractive surgery (thin cornea, high refractive error beyond LASIK/PRK range, retained accommodation desired): phakic IOL (ICL) is a good option provided anterior chamber depth and endothelial cell count are adequate.

Key sources

• Kanski's Clinical Ophthalmology, 10th ed. (IOL design, materials, biometry, PCO, dysphotopsia, malposition) - pp. 332-336, 613
• The Wills Eye Manual (UGH syndrome, biometry indications, postoperative complications)
• Cochrane systematic reviews: Trifocal vs EDOF IOLs (PMID 38984608, 2024); Trifocal vs bifocal IOLs (PMID 36705482, 2023)
• AJO meta-analysis: EDOF vs Trifocal IOLs (PMID 36736751, 2023)
• BMC Ophthalmology network meta-analysis of presbyopia-correcting IOLs (PMID 38627651, 2024)

Macular Hole - Recent Advances (PG Ophthalmology Notes)

Quick Recap - Basics (for context)

• Definition: full-thickness macular hole (FTMH) = interruption of all retinal layers from the internal limiting membrane (ILM) to the RPE at the fovea, most commonly idiopathic due to anteroposterior and tangential vitreofoveal traction.
• Staging (Gass): Stage 1 (impending, foveal detachment without full-thickness defect) -> Stage 2 (small FTMH <400 um with operculum) -> Stage 3 (FTMH >400 um with persistent vitreomacular attachment) -> Stage 4 (FTMH with complete posterior vitreous detachment).
• OCT is the key diagnostic and staging tool (fluorescein angiography is unnecessary).
• Natural history: ~50% of Stage 1 holes resolve spontaneously after vitreofoveal separation; ~10% of FTMH close spontaneously. Fellow-eye risk is ~10% over 5 years if PVD has not occurred.
• Gold standard treatment: pars plana vitrectomy (PPV) with ILM peeling and gas tamponade, ideally within 6 months of onset - closure rates >90% for small/medium holes (<400 um) (Wills Eye Manual, p. 630; Kanski's Clinical Ophthalmology, p. 628).

Recent Advances

1. Inverted ILM Flap Technique

• Instead of complete ILM removal, a strip of ILM is left attached at the hole margin and folded/tucked into the hole ("inverted") to act as a scaffold for glial proliferation and hole closure.
• Significantly improves closure rates in large and myopic macular holes compared with conventional ILM peeling alone, and is now considered a standard modification for large/refractory holes.
• Variants: temporal inverted ILM flap, free ILM flap transplantation (harvested from elsewhere and placed over a hole with no adjacent ILM available, e.g., after failed prior peeling).

2. Autologous Retinal Transplantation (ART)

• A small free graft of autologous peripheral retina (full or partial thickness) is harvested and placed into/over the hole bed to promote closure and possibly photoreceptor integration.
• Used mainly for refractory/reopened holes after failed primary surgery where no ILM remains for flap techniques.
• Reported to achieve anatomical closure in a majority of otherwise unclosable holes, though visual gains are variable and technically demanding.

3. Amniotic Membrane Grafting (AMT)

• A small piece of human amniotic membrane (rich in growth factors, anti-inflammatory and anti-fibrotic properties) is inserted into the hole as a biological patch/scaffold.
• Alternative to ART in eyes lacking suitable ILM or retinal donor tissue; growing evidence supports its use in large and chronic refractory holes.

4. Lens Capsule Transplantation

• Anterior or posterior lens capsule (often harvested during combined phaco-vitrectomy) is used as a free graft plug for the hole, providing another biological scaffold option in refractory cases, particularly where ILM/retina/amniotic tissue is unavailable or contraindicated.

5. Subretinal Fluid Injection / "Macular Hole Rim Attenuation" Technique

• For very large, persistent holes: a localized subretinal detachment is induced at the posterior pole via subretinal balanced salt solution (BSS) injection, followed by attenuation/relaxation of the hole rim during fluid-air exchange to allow the edges to be apposed and closed.
• A promising newer option specifically for holes considered otherwise unclosable.

6. Nonvitrectomizing Vitreous Surgery (NVS)

• Emerging minimally invasive approach for selected macular holes that avoids full vitrectomy, aiming to reduce surgical risk/recovery time; still investigational with limited case series data (2025 literature).

7. Pharmacologic Vitreolysis - Ocriplasmin

• Intravitreal ocriplasmin (a recombinant protease) can induce pharmacologic vitreofoveal separation, offering a non-surgical option for small (<400 um) FTMH with vitreomacular traction and no significant epiretinal membrane.
• Closure rates are modest (~25-40% in trials, lower than surgery) and best reserved for small holes with focal vitreomacular adhesion; not effective for larger or chronic holes.
• Now used less frequently in many centers given availability and reliability of surgery, but remains a relevant PG topic for non-surgical management.

8. Other Nonsurgical Approaches (evidence still limited - scoping review 2024, PMID 38677557)

• Topical/periocular/intravitreal NSAIDs, corticosteroids, and carbonic anhydrase inhibitors have been explored, particularly for holes with associated cystoid macular edema, with reported closure rates in this niche group (73-84% in selected small studies) - but overall evidence is weak and inconsistent, and these are not standard of care.
• Intravitreal gas injection alone (without vitrectomy) has been tried for small holes with modest closure rates (~55%).
• Anti-VEGF has been explored in select settings (e.g., holes with subretinal neovascularization or in myopic hole-related pathology) but is not an established primary treatment.
• Bottom line: nonsurgical options can be considered for Stage 1 holes (observation) or select small/traumatic holes, but PPV with ILM peel remains the gold standard for all full-thickness holes requiring intervention.

9. Adjuncts and Technical Refinements

• Autologous blood/platelet-rich plasma instillation into the hole bed to enrich growth factors and promote closure, used as an adjunct in some refractory cases.
• Increasing use of intraoperative OCT for real-time confirmation of flap positioning and hole architecture during complex refractory hole surgery.
• Refinement of tamponade choice (long-acting gas vs silicone oil) individualized to hole size and chronicity, especially in myopic macular holes with retinoschisis/detachment where the best technique remains debated.

Exam-Focused Summary Table

Key sources

• Kanski's Clinical Ophthalmology, 10th ed., pp. 627-630
• The Wills Eye Manual, Gass staging and treatment section, pp. 629-631
• Meshkin RS, Eliott D. "Refractory Macular Hole Surgery: A Review of Recent Surgical Innovations." Int Ophthalmol Clin. 2025 (PMID 40601506)
• Arda H et al. "Advances in management strategies for large and persistent macular hole: An update." Surv Ophthalmol. 2024 (PMID 38552678)
• Lee YM et al. "Scoping review of nonsurgical treatment options for macular holes." Surv Ophthalmol. 2024 (PMID 38677557)
• Grieco G et al. "Updates on surgical and nonsurgical innovations for macular hole treatment." Surv Ophthalmol. 2025 (PMID 41237971)

Summary Table: Recent Advances in Macular Hole Management

Recent Trends in Diagnostic Modalities for Macular Edema (PG Ophthalmology Notes)

1. Classical/Baseline Diagnostic Modalities (context)

• Clinical examination: irregular/blunted foveal reflex, macular thickening on slit-lamp biomicroscopy with contact/non-contact lens.
• Fundus fluorescein angiography (FA): classic "flower-petal"/petaloid pattern of cystoid macular edema (CME) due to dye pooling in Henle's fiber layer cysts; shows vascular leakage, microaneurysms, capillary non-perfusion. Long considered the reference standard for detecting leakage but invasive (dye-related reactions) and limited in structural detail.
• Optical Coherence Tomography (OCT): now the primary modality for detecting and monitoring macular edema - shows intraretinal cystic spaces, retinal thickening, subretinal fluid, and disruption of outer retinal layers. Cross-sectional, non-invasive, quick, and repeatable, making it the standard for diagnosis, staging, and monitoring treatment response (Wills Eye Manual, p. ~460; Kanski's Clinical Ophthalmology, p. ~500s; Harrison's Principles of Internal Medicine, 22nd ed.).

2. Recent Trends and Advances

A. OCT Angiography (OCTA)

• Non-invasive, dye-free imaging of retinal and choroidal vasculature using motion contrast, avoiding the risks of intravenous dye.
• Increasingly used to assess capillary non-perfusion, microaneurysms, and foveal avascular zone (FAZ) changes in diabetic macular edema (DME) without the need for fluorescein injection.
• Useful for detecting macular neovascularization masked by edema - recent work combining OCTA with deep learning models has improved detection of occult neovascularization in eyes presenting with macular edema (Wongchaisuwat et al., 2025, PMID 39461425).
• Comparative studies show OCTA correlates reasonably well with FA for detecting DME-related vascular changes, though OCTA is prone to motion and segmentation artifacts, especially in eyes with significant edema distorting normal retinal layer boundaries (Tamer Kaderli et al., 2024, PMID 38447922; Niewiem et al., 2025, PMID 40804838).
• Emerging OCTA-specific biomarkers such as SSPiM (subclinical/specific perifoveal pattern) are being studied as predictors of treatment response in DME (2024 literature).

B. Swept-Source OCT (SS-OCT) and Biomarker-Based OCT Analysis

• Swept-source OCT allows deeper penetration (better choroidal visualization), faster scan speed, and reduced motion artifact compared with spectral-domain OCT.
• Recent studies use SS-OCT combined with OCTA to identify quantitative structural biomarkers predicting treatment response in treatment-naive DME, including:
  • Hyperreflective foci (HRF) - thought to represent activated microglia/inflammatory cells, associated with outer blood-retinal barrier breakdown.
  • Disorganization of retinal inner layers (DRIL)
  • Subretinal fluid presence
  • Ellipsoid zone (photoreceptor) integrity
  • Central subfield thickness and cystoid space morphology
• These structural biomarkers are being positioned as prognostic/predictive tools to guide individualized (phenotype-driven) anti-VEGF or steroid therapy rather than a one-size-fits-all treatment approach (Rezende et al., 2025, PMID 40264206; Frontiers in Medicine 2026 review).

C. Artificial Intelligence / Deep Learning-Assisted Diagnosis

• Deep learning models are increasingly applied to:
  • Automated detection and quantification of macular edema and cystoid spaces on OCT.
  • Differentiating etiology of edema - e.g., a 2025 multimodal deep learning approach using OCT plus infrared imaging to distinguish macular edema secondary to retinal vein occlusion from diabetic macular edema (Barbosa et al., 2025, PMID 39941677).
  • Detecting occult macular neovascularization on OCTA in edematous eyes (as above).
• These tools aim to reduce inter-observer variability, enable automated screening, and support treatment-decision algorithms, though they remain largely investigational/adjunctive rather than replacing clinician interpretation.

D. Multimodal Imaging Approach

• Current trend favors combining multiple modalities (OCT + OCTA + FA + fundus autofluorescence + infrared imaging) rather than relying on a single test, to build a fuller picture of edema etiology, chronicity, and treatment response.
• Multimodal imaging is being explored not just diagnostically but as a source of prognostic and predictive biomarkers guiding anti-VEGF, steroid, or laser therapy selection (Parravano et al., Survey of Ophthalmology 2024).
• Ultra-widefield FA/imaging is gaining use to assess peripheral non-perfusion contributing to edema, particularly in diabetic retinopathy and retinal vein occlusion, beyond the standard 30-55 degree field.

E. Inflammatory and Molecular Biomarkers (Adjunctive, Research-Level)

• Growing interest in aqueous/vitreous cytokine biomarkers (VEGF, IL-6, IL-8, MCP-1) correlating with OCT-derived structural findings (e.g., hyperreflective foci) to characterize the inflammatory phenotype of DME, supporting a shift toward "phenotype-driven" management (2024-2026 literature).
• These are not yet routine clinical diagnostic tools but represent an active research trend linking imaging findings to underlying pathophysiology.

F. Laser Photocoagulation Response Assessment via OCTA

• OCTA is being used not only for diagnosis but to monitor efficacy of focal/grid laser photocoagulation in DME by tracking changes in capillary perfusion and edema staging over time (Fu et al., 2024, PMID 38508440).

G. Faricimab and Imaging Correlation

• With newer anti-VEGF/Ang-2 dual inhibitors like faricimab, recent studies are characterizing corresponding OCT and OCTA changes with treatment (e.g., resolution of hyperreflective foci, changes in FAZ), helping refine imaging-based treatment response criteria (Śpiewak et al., 2025, PMID 40733068).

3. Exam-Focused Summary Table

Key Sources

• Kanski's Clinical Ophthalmology, 10th ed.; The Wills Eye Manual; Harrison's Principles of Internal Medicine, 22nd ed. (baseline OCT/FA teaching)
• Wongchaisuwat N et al. "Detection of Macular Neovascularization in Eyes Presenting with Macular Edema using OCT Angiography and a Deep Learning Model." Ophthalmol Retina. 2025 (PMID 39461425)
• Rezende MP et al. "Prospective and dichotomous study of biomarkers with swept-source OCT and OCT-angiography in naive patients with diabetic macular edema." Int J Retina Vitreous. 2025 (PMID 40264206)
• Barbosa G et al. "Deep Learning to Distinguish Edema Secondary to Retinal Vein Occlusion and Diabetic Macular Edema: A Multimodal Approach Using OCT and Infrared Imaging." J Clin Med. 2025 (PMID 39941677)
• Tamer Kaderli S et al. "Clinical Features Related to OCT Angiography Artifacts in Patients with Diabetic Macular Edema." Ophthalmol Retina. 2024 (PMID 38447922)
• Parravano M et al. "Multimodal imaging in diabetic retinopathy and macular edema." Surv Ophthalmol. 2024
• Śpiewak D et al. "Efficacy of Faricimab in the Treatment of Diabetic Macular Edema and Faricimab-Related Changes in OCT and OCT Angiography." Pharmaceutics. 2025 (PMID 40733068)

Confocal Microscopy - Principles and Applications (PG Ophthalmology Notes)

1. Basic Principle

• Confocal microscopy is an optical imaging technique that increases resolution and contrast by using a spatial pinhole to eliminate out-of-focus light (glare) from the image, so only light from a single focal plane reaches the detector.
• Optical sectioning: by focusing the illumination source and detection pathway on the exact same point simultaneously ("confocal" = sharing the same focus), the instrument captures a thin, in-focus 2D image at a chosen depth while blocking scattered light from planes above and below.
• Multiple thin optical sections at different depths can be captured and digitally stacked/reconstructed to build a three-dimensional representation of tissue architecture, without physically sectioning the tissue (hence "in vivo" or "noninvasive optical biopsy").
• Types of illumination used clinically:
  • Slit-scanning confocal microscopy
  • Laser-scanning confocal microscopy (most widely used - uses a laser source and a scanning mirror system to raster the beam across the tissue)
  • Tandem scanning confocal microscopy (uses a rotating Nipkow disc with multiple pinholes)
• In ophthalmology, the technique is most developed for the cornea, since the eye's optical clarity allows direct high-resolution imaging of all corneal layers (epithelium, Bowman's layer, stroma, Descemet's membrane, and endothelium) in a living patient without a biopsy.

2. Why Confocal Microscopy Works Well in the Eye

• The cornea is thin, transparent, and avascular - ideal for transillumination-based optical sectioning.
• Provides cellular-level resolution (comparable in some respects to light microscopy of a histologic section) but obtained entirely non-invasively and in real time.
• Requires reasonably clear ocular media and adequate patient fixation and cooperation, since alignment in the same focal plane is needed for meaningful comparative/serial imaging (Wills Eye Manual, p. 1107).

3. Applications in Ophthalmology

A. Infectious Keratitis

• One of the most valuable clinical uses: rapid, non-invasive detection of Acanthamoeba (cysts appear as round, highly reflective double-walled structures) and fungal elements (branching hyphae) directly in the corneal stroma, allowing early diagnosis and institution of definitive therapy without waiting for culture results.
• Kanski's Clinical Ophthalmology notes that confocal microscopy "frequently permits identification of organisms in vivo, but is not widely available outside tertiary centers."

B. Corneal Endothelium

• Excellent for imaging the endothelial cell layer and obtaining endothelial cell density, morphology, and pleomorphism/polymegathism measurements - useful in Fuchs endothelial dystrophy, iridocorneal endothelial (ICE) syndrome, pseudophakic corneal edema, and pre-/post-keratoplasty assessment.

C. Corneal Dystrophies and Structural Disease

• Visualizes deposits and structural changes in stromal and epithelial corneal dystrophies at a cellular level.
• Used in iridocorneal endothelial syndrome and epithelial downgrowth after intraocular surgery, helping confirm diagnosis when clinical findings are equivocal.

D. Corneal Nerves / Neuropathies

• Images subbasal corneal nerve plexus morphology (nerve fiber density, branching, tortuosity), which is reduced in diabetic peripheral neuropathy, dry eye disease, and small fiber neuropathy - increasingly used as a surrogate biomarker for systemic peripheral neuropathy severity and progression (recent literature, e.g., Petrović et al. 2025, PMID 40941695; Chiang et al. 2023, PMID 37336941).
• Useful in evaluating neurotrophic keratopathy and post-refractive surgery nerve regeneration.

E. Dry Eye Disease and Ocular Surface/Allergic Disease

• Assesses inflammatory cell infiltration (dendritic/Langerhans cells), goblet cell density, and nerve changes in dry eye disease and ocular pain syndromes (Shetty et al. 2023, PMID 37026240).
• Applied to ocular allergic disease and conjunctival pathology to characterize inflammatory cell profiles non-invasively (Şimşek et al. 2024, PMID 39743938; Yu et al. 2024, PMID 39482793).

F. Limbal Stem Cell Deficiency

• Confirms conjunctivalization of the cornea by identifying goblet cells on the corneal surface, supporting the diagnosis of limbal stem cell deficiency (alongside impression cytology and cytokeratin-19 immunostaining) - Kanski's Clinical Ophthalmology.

G. Contact Lens-Related Changes

• Studies keratocyte density, stromal acidosis/hypoxia, and corneal sensitivity changes associated with long-term contact lens wear.

H. Keratoconus and Ectatic Disease

• Detects microstructural stromal and epithelial changes in manifest, subclinical, and topographically-normal-but-genetically-related keratoconus cases, sometimes before topographic signs manifest.

I. Systemic Disease Associations

• Corneal nerve and immune cell changes on confocal microscopy have been studied in Sjögren syndrome, Fabry disease (cornea verticillata, stromal haze), and diabetes, positioning corneal confocal microscopy as a non-invasive "window" into systemic neuropathy and microvascular/metabolic disease.

4. Recent/Research Trends

• Expanding role as a biomarker tool for systemic small-fiber neuropathy (diabetes, chemotherapy-induced neuropathy) via corneal subbasal nerve analysis - an active area of translational research linking ophthalmic imaging to systemic disease monitoring.
• Broader "comprehensive review" literature (2024-2025) increasingly frames in vivo confocal microscopy as a tool spanning cornea AND conjunctiva, useful across infectious, inflammatory, dystrophic, and neuropathic ocular surface disease (Ramirez-Miranda et al. 2025, PMID 40501480).
• Combined/multimodal use with anterior segment OCT is being explored for more complete structural and cellular characterization of corneal pathology.

5. Limitations

• Requires patient fixation and reasonably clear media.
• Field of view is small at any single scan, requiring multiple images/mosaicking for a broader survey.
• Limited availability outside tertiary/specialized centers.
• Operator-dependent image acquisition and interpretation; serial/comparative studies need precise focal-plane alignment between visits.

Key Sources

• The Wills Eye Manual, Section 14.14 Confocal Microscopy, p. 1107
• Kanski's Clinical Ophthalmology, 10th ed. (limbal stem cell deficiency, microbial keratitis investigations)
• Chiang JCB et al. "In-vivo corneal confocal microscopy: Imaging analysis, biological insights and future directions." Commun Biol. 2023 (PMID 37336941)
• Shetty R et al. "Role of in vivo confocal microscopy in dry eye disease and eye pain." Indian J Ophthalmol. 2023 (PMID 37026240)
• Ramirez-Miranda A et al. "In vivo Confocal Microscopy for Corneal and Ocular Surface Pathologies: A Comprehensive Review." Clin Ophthalmol. 2025 (PMID 40501480)
• Yu M et al. "A review of the application of in-vivo confocal microscopy on conjunctival diseases." Eye Vis (Lond). 2024 (PMID 39482793)

Anterior Segment OCT (AS-OCT) - Principles, Applications, and Comparison with UBM

1. Principle of AS-OCT

• OCT is a non-invasive, non-contact imaging technique that generates 2D/3D cross-sectional images by measuring the optical reflectance/backscatter of light, analogous to ultrasound but using light instead of sound.
• A superluminescent diode emits low-coherence light, split into a sample beam (directed at the tissue) and a reference beam (directed at a reference mirror). An interferometer measures the time delay and intensity of light reflected from different tissue depths, and this is reconstructed into a cross-sectional image.
• Wavelength difference matters: posterior segment OCT uses ~820 nm wavelength light; anterior segment OCT uses a longer wavelength (~1310 nm), which penetrates the sclera and pigmented tissue better and reduces scatter, giving better visualization of the cornea, angle, and anterior chamber structures.
• Resolution is very high (down to a few microns), though anterior segment-dedicated systems trade some resolution for greater depth of field to capture the whole angle-to-angle span in one scan.
• Technology evolution: time-domain OCT -> spectral-domain OCT (SD-OCT, faster acquisition, higher resolution, fewer motion artifacts) -> swept-source OCT (SS-OCT, longer wavelength, deeper tissue penetration, less signal attenuation from pigmented/opaque structures - especially advantageous for anterior segment and angle imaging).
• OCT angiography (OCT-A) principles can also be adapted to the anterior segment for imaging conjunctival/corneal/iris vasculature, though with a small field of view and need for patient cooperation.

2. Applications of AS-OCT

• Primary expanding use: evaluation of angle-closure glaucoma, demonstrating the relationship of the peripheral iris to the trabecular meshwork/filtration angle.
• Quantitative angle parameters: angle opening distance (AOD), trabecular-iris surface area (TISA), angle recess area (ARA) - measured objectively rather than relying only on gonioscopy.
• Useful for detecting plateau iris configuration, and for pre- and post-laser peripheral iridotomy angle assessment.

• Corneal pachymetry (thickness mapping), assessment of corneal opacities/scars, dystrophies, and depth of pathology (e.g., depth of infiltrate in keratitis, depth of invasion in ocular surface squamous neoplasia [OSSN], limbal dermoids).
• Pre- and post-refractive surgery imaging (flap thickness in LASIK, assessing ectasia).
• Detecting subtle findings not visible on slit lamp, e.g., early Kayser-Fleischer rings (linear hyperreflective material in peripheral cornea) in Wilson disease.
• Used alongside/complementary to Scheimpflug tomography and Placido-based topography for anterior/posterior corneal curvature and elevation mapping.

• Swept-source AS-OCT can sensitively detect individual inflammatory cells in the anterior chamber, useful in uveitis assessment.

• Depth and extent assessment of iris cysts, anterior iris/ciliary body tumors, and differentiating some lesions from ciliary body tumors (limited by shadowing from pigmented/keratinized lesions).

• OSSN and other conjunctival/corneal surface lesions - AS-OCT shows a clear advantage here, providing intralesional detail useful for diagnosis, management planning, and monitoring treatment response.

• Assessing depth of foreign bodies, wound architecture, and structures anterior to the iris plane after trauma or surgery (e.g., IOL position relative to iris, filtering bleb morphology after glaucoma surgery).

3. AS-OCT vs Ultrasound Biomicroscopy (UBM) - Key Differences

4. Advantages of AS-OCT over UBM

• Non-contact - no risk of corneal abrasion, no need for topical anesthesia or an eye cup, better patient tolerance (especially useful in children, post-surgical eyes, or eyes with epithelial defects/infection where contact is contraindicated).
• Faster acquisition and easier to perform - less operator-dependent, more reproducible across examiners and visits.
• Higher axial resolution for superficial anterior segment structures (cornea, angle, anterior iris surface) - better for detailed corneal and OSSN imaging.
• Better suited for serial monitoring in glaucoma or corneal disease given its speed and comfort, and integrates naturally with posterior segment OCT platforms many clinics already have.
• Lower risk of infection transmission (no direct globe contact), and no risk of iatrogenic epithelial trauma.

5. Disadvantages of AS-OCT compared to UBM

• Cannot image structures posterior to the iris pigment epithelium well - poor visualization of ciliary body, zonules, pars plicata, and posterior chamber lens equator, which is a major limitation for tumors or pathology in this region.
• Shadowing artifact from pigmented (iris, ciliary body) or opaque/keratinized tissue significantly limits visualization of the posterior border of pigmented lesions - UBM is superior here.
• Media opacity (corneal scarring, blood, dense cataract in the periphery) degrades image quality more than with ultrasound, since light scatters more than sound in opaque tissue.
• Field of view/depth of penetration is inherently more limited than UBM for deep anterior segment structures.
• For non-pigmented iris tumors, UBM has shown superior reproducibility in identifying the posterior lesion border compared to AS-OCT in comparative studies.

6. Summary / Exam Take-Home

• AS-OCT and UBM are complementary, not competing, technologies - both correlate well with histopathology and provide useful information on lesion size, extension, and morphology, but neither replaces biopsy when tissue diagnosis is required.
• Choose AS-OCT for: angle-closure glaucoma workup, corneal pathology, anterior chamber inflammation, OSSN, and any situation needing a quick, comfortable, non-contact scan of structures from the ocular surface to the iris plane.
• Choose UBM for: suspected ciliary body pathology (tumors, cysts), cyclodialysis cleft, hypotony workup, plateau iris with posterior chamber detail, IOL-ciliary body relationships (UGH syndrome), and any lesion where visualization behind the iris is essential.

Key Sources

• Kanski's Clinical Ophthalmology, 10th ed., "Imaging in glaucoma" section, pp. 371-372 (UBM and AS-OCT principles, AOD/TISA parameters, Fig. 11.14-11.15)
• The Wills Eye Manual, Section 14.12, pp. 1104-1105 (OCT principle, wavelength, uses)
• Bianciotto CG et al., IOVS 2010 - Comparison of UBM vs AS-OCT for anterior segment tumors
• Kottaridou E et al. "Imaging of Anterior Segment Tumours: A Comparison of Ultrasound Biomicroscopy and Anterior Segment OCT." PMC 2024 (PMID/PMC10798380)
• EyeWiki - Ultrasound Biomicroscopy (UBM vs AS-OCT comparative section)

Optical Coherence Tomography (OCT) - Long Note (PG Ophthalmology Exam)

1. Introduction

2. Basic Principle

• A superluminescent diode emits low-coherence light, split into a sample beam (directed into the eye) and a reference beam (directed to a reference mirror).
• Light reflected from different depths within the tissue is compared with the reference beam using an interferometer; the time delay and intensity of each reflection is used to build a depth profile (A-scan), and multiple A-scans are combined to form a cross-sectional B-scan image.
• Wavelength: ~820 nm superluminescent diode light is used for posterior segment (retinal) imaging; ~1310 nm (longer wavelength) is used for anterior segment imaging, as it penetrates the sclera/pigmented tissue better with less scatter.
• Resolution: modern systems achieve axial resolution of a few microns (as low as 3-5 um), far superior to ultrasound.
• Reflectivity patterns: highly reflective (hyperreflective) structures include the retinal nerve fibre layer and RPE, and pathologically, dense pigment, fibrous scar tissue, subhyaloid blood, and hard exudates. Low reflectivity (hyporeflective) is seen with intraretinal or subretinal fluid, and cystic spaces.

3. Evolution of OCT Technology

4. OCT Angiography (OCT-A)

• Uses motion contrast from erythrocyte movement within vessels across repeated B-scans to generate images of retinal and choroidal (and anterior segment) microvasculature without dye injection.
• Allows visualization of the superficial and deep capillary plexus, foveal avascular zone (FAZ), and abnormal neovascular complexes (e.g., choroidal neovascularization, diabetic retinopathy-related non-perfusion).
• Advantages: non-invasive, fast, avoids dye-related adverse reactions, allows depth-resolved (en face) visualization of specific vascular layers.
• Limitations: small field of view (though wide-field systems are emerging), motion and segmentation artifacts, cannot show dynamic leakage (no true "angiography" of dye transit), and requires good patient cooperation and fixation.
• TIP (Kanski's Clinical Ophthalmology): OCT-A is particularly useful for visualizing abnormal vessels in AMD, diabetic retinopathy, and other disorders, and for objective monitoring of disease after treatment.

5. Clinical Applications of OCT

A. Retina

• Macular disease: macular edema (diabetic, post-RVO, uveitic), central serous chorioretinopathy, AMD (drusen, CNV, geographic atrophy), cystoid macular edema, macular holes, epiretinal membranes, vitreomacular traction, retinal detachment, pigment epithelial detachment, retinal tumors, hard exudates.
• Vitreoretinal interface abnormalities: macular hole staging, epiretinal membrane, vitreomacular traction, subhyaloid hemorrhage.
• Enhanced depth imaging is used to characterize choroidal thickness and lesions (e.g., choroidal tumors, central serous chorioretinopathy).

B. Glaucoma

• Quantification of retinal nerve fibre layer (RNFL) thickness, ganglion cell complex (GCC)/ganglion cell-inner plexiform layer analysis, and optic nerve head parameters (cup volume, rim area) for early diagnosis and progression monitoring.
• RNFL defects on OCT are known to precede visual field changes in glaucoma, making OCT valuable for early detection.
• Reports typically display global loss volume (GLV) and focal loss volume (FLV) metrics.

C. Anterior Segment (AS-OCT)

• Angle-closure glaucoma evaluation (angle opening distance, trabecular-iris surface area), corneal pathology, pachymetry, anterior chamber inflammation (cell counting with swept-source systems), ocular surface tumors, and depth assessment of corneal/limbal lesions.

D. Neuro-ophthalmology

• RNFL and ganglion cell layer thickness assessment in optic neuritis, multiple sclerosis, papilledema/disc edema, compressive optic neuropathies, and optic nerve drusen (best seen with EDI-OCT as signal-poor round structures at or below the disc surface).
• Serves as a structural biomarker of axonal loss, correlating with visual field and visual acuity outcomes, and is increasingly used in neurology for monitoring optic nerve involvement in systemic neurological disease.

E. Pediatric Ophthalmology

• OCT and OCT-A increasingly used in pediatric retinal disease (retinopathy of prematurity, pediatric uveitis, inherited retinal disease), though handheld and sedation-free protocols are needed given cooperation challenges.

6. Image Interpretation - Key Points

• Normal retina shows characteristic hyperreflective bands for the nerve fibre layer, external limiting membrane, ellipsoid zone (photoreceptor inner segments), and RPE/Bruch's membrane complex, with hyporeflective bands for the outer and inner nuclear/plexiform layers.
• Diagnostic clues:
  • Intraretinal cystic spaces -> cystoid macular edema
  • Subretinal fluid -> exudative/serous detachment (CSCR, wet AMD)
  • Disruption of ellipsoid zone/outer retina -> photoreceptor damage, poor visual prognosis marker
  • Hyperreflective foci -> activated microglia/inflammatory markers, seen in diabetic macular edema
  • Disorganization of retinal inner layers (DRIL) -> marker of ischemia, correlates with poor visual outcome

7. Artifacts and Limitations

• Motion artifacts (patient movement, poor fixation)
• Media opacity (cataract, corneal scarring, vitreous hemorrhage) degrades signal
• Segmentation errors in automated layer analysis software, especially in distorted retinal architecture (large cysts, subretinal fluid, tilted discs)
• OCT-A specific: projection artifacts, motion artifacts, small field of view, inability to detect leakage
• OCT is a structural, not functional test - always interpreted alongside clinical exam, visual fields, and other functional tests (a key exam teaching point, especially for glaucoma).

8. Recent Advances (for "latest trends" exam questions)

• Widefield/ultra-widefield OCT and OCT-A systems now allow peripheral retinal and vascular imaging beyond the traditional posterior pole.
• AI/deep learning-assisted OCT analysis: automated segmentation, disease classification, biomarker quantification (e.g., hyperreflective foci, DRIL), and prediction of treatment response - increasingly integrated into commercial OCT platforms.
• OCT-A moving toward clinical mainstream for systemic disease biomarkers (e.g., retinal/choroidal microvascular changes in cardiovascular disease, neurodegenerative disease) - Chua J et al., Prog Retin Eye Res 2024 (PMID 39218142).
• Continued refinement of swept-source OCT-A for faster, deeper, wider-field vascular imaging with fewer artifacts (Zheng F et al., 2023, PMID 37846376; Hormel TT, Jia Y, 2025, PMID 40995309).
• Expanding neuro-ophthalmic applications, including OCT-based monitoring of optic nerve disease progression and as a trial outcome measure in neuroprotection studies (Ge JY et al., 2024, PMID 38214066; Shin HJ, Costello F, 2024, PMID 38961147).

9. Exam-Style Summary Points

• OCT = light-based interferometric imaging; analogous to ultrasound but with light, giving much higher resolution.
• SD-OCT has replaced TD-OCT as standard of care; SS-OCT offers deeper penetration and faster speed.
• EDI-OCT is specifically for choroidal/deep structure visualization (e.g., disc drusen, choroidal thickness).
• OCT-A gives dye-free vascular imaging but cannot show leakage (a common exam distinction vs FA).
• RNFL thinning on OCT precedes visual field defects in glaucoma - a frequently tested concept.
• OCT is structural; always correlate with function (visual fields, visual acuity, ERG) - never diagnose in isolation.

Key Sources

• The Wills Eye Manual, Section 14.12, pp. 1104-1105
• Kanski's Clinical Ophthalmology, 10th ed. (Investigation of macular disease and Imaging in glaucoma sections, pp. 371-372, 579)
• Bradley and Daroff's Neurology in Clinical Practice, OCT for retinal and optic neuropathy assessment sections
• Histology: A Text and Atlas (SD-OCT retinal layer correlation)
• Tsang SH, Sharma T. "Optical Coherence Tomography." Adv Exp Med Biol. 2025 (PMID 40736805)
• Langlo CS et al. "Optical coherence tomography retinal imaging: narrative review of technological advancements and clinical applications." Ann Transl Med. 2025 (PMID 40438521)
• Chua J et al. "Optical coherence tomography angiography of the retina and choroid in systemic diseases." Prog Retin Eye Res. 2024 (PMID 39218142)
• Hormel TT, Jia Y. "Advancing optical coherence tomography angiography to the clinic." Taiwan J Ophthalmol. 2025 (PMID 40995309)

Ultra-Widefield (UWF) Retinal Imaging - Note for PG Ophthalmology Exam

1. Introduction

2. Definitions and Terminology (Kanski's Clinical Ophthalmology)

3. Principle / Technology

• Most UWF systems use scanning laser ophthalmoscopy (SLO) technology - low-power laser light (typically red and green wavelengths) is scanned across the retina and confocal detection is used to build the image, rather than relying on a flash-based camera and optical lens system.
• The ellipsoidal mirror design (e.g., Optos system) allows capture of an ultra-widefield image (up to 200 degrees) through a small pupil without requiring dilation in most cases, because the scanning laser beam is steered around the natural optical limitations of a small pupil aperture.
• Some platforms use contact lens-based wide-angle optics attached to a standard camera/laser system to achieve similarly wide fields, and montage techniques stitch multiple standard-field images together to approximate pan-retinal views (up to ~267 degrees with 6-image montage).
• Many UWF devices integrate multiple imaging modalities on the same platform: colour fundus photography, fundus autofluorescence (FAF), and fluorescein angiography (FA) can all be performed in ultra-widefield mode, giving multimodal peripheral retinal assessment in one sitting.

4. Advantages

• Captures the peripheral retina in a single image without extensive pupil dilation, reducing patient discomfort and photophobia, and useful in patients who cannot tolerate prolonged dilation or indirect ophthalmoscopy (children, uncooperative patients).
• Provides an objective, reproducible, storable image for documentation, comparison over time, and telemedicine/screening programs.
• Enables ultra-widefield fluorescein angiography (UWF-FA) to detect peripheral non-perfusion, neovascularization, and vascular leakage that would be missed by standard 7-field or posterior-pole FA - now well established in diabetic retinopathy, where peripheral non-perfusion and peripheral lesions detected by UWF imaging predict a higher risk of DR progression.
• Faster than performing multiple standard-field photographs or building a montage manually.
• Useful adjunct for telescreening and remote grading of diabetic retinopathy and retinopathy of prematurity.

5. Applications in Ophthalmology

A. Diabetic Retinopathy (most extensively studied application)

• UWF colour imaging and UWF-FA identify peripheral lesions and non-perfusion not captured by the traditional ETDRS 7-standard-field photography.
• Peripheral non-perfusion and peripheral retinal lesions on UWF imaging are associated with, and predictive of, more severe diabetic retinopathy and higher risk of progression over time.
• Improves detection and accurate classification/staging of diabetic retinopathy compared with standard field imaging.
• Helps guide targeted peripheral laser (panretinal photocoagulation) planning by mapping the full extent of non-perfused retina.

B. Retinal Vein Occlusion (RVO)

• UWF-FA is valuable for quantifying the extent of peripheral retinal ischemia/non-perfusion in branch and central RVO, which correlates with risk of neovascular complications and helps guide treatment/laser decisions.
• UWF-OCT angiography is emerging as a complementary dye-free method for assessing vascular changes in RVO.

C. Uveitis / Retinal Vasculitis

• Particularly helpful in conditions with peripheral vasculitis or peripheral neovascularization (e.g., sarcoidosis, tuberculosis, Behçet disease), and vaso-occlusive peripheral disease as seen in sickle cell retinopathy, where wide-field imaging is especially suited to evaluate peripheral vascular changes and neovascularization "sea fans."
• Kanski's Clinical Ophthalmology specifically highlights wide-field imaging as "especially helpful" in retinal vasculitis workup and sickle cell retinopathy evaluation.

D. Retinopathy of Prematurity (ROP) and Pediatric Retina

• Wide-field pediatric imaging systems (e.g., RetCam and similar) allow documentation of peripheral retinal vascularization status, plus/disease features, and stage of ROP without requiring binocular indirect ophthalmoscopy alone - useful for screening, telemedicine consultation, and serial documentation/comparison.
• Also used in pediatric conditions such as familial exudative vitreoretinopathy (FEVR), where UWF imaging aids early diagnosis of peripheral avascular zones and neovascularization.

E. Peripheral Retinal Degenerations and Tumors

• Documentation and monitoring of peripheral lesions such as cystic retinal tufts, lattice degeneration, retinal detachment extent, and peripheral tumors (e.g., choroidal melanoma, retinoblastoma extent) - wide-field imaging has improved recognition of previously under-detected peripheral lesions.

F. Age-related Macular Degeneration and Other Posterior Pole Disease

• Even though AMD is primarily a macular disease, UWF FAF/colour imaging can identify peripheral drusen-like deposits and reticular pigmentary changes with prognostic relevance in some studies.

6. Limitations

• Peripheral image quality can be degraded by eyelid/eyelash artifacts, and peripheral distortion is inherent to the wide-angle optical projection (images are not a true-to-scale flat representation of the curved retina - peripheral structures appear compressed/distorted).
• Media opacities (cataract, vitreous haemorrhage) still degrade image quality as with any fundus imaging technique.
• Cost and availability - dedicated UWF devices are more expensive than standard fundus cameras and not universally available, particularly in resource-limited settings.
• UWF-FA still requires intravenous dye injection with its associated (though rare) risks of allergic reaction.
• Standardization challenges: not all UWF systems have identical field-of-view, colour rendition, or image processing, complicating comparison of data across studies and devices.

7. Recent Trends and Advances

• Ultra-widefield OCT and OCT angiography: emerging systems now extend swept-source OCT-A capability toward wider fields, enabling dye-free visualization of peripheral non-perfusion in diabetic retinopathy and RVO (complementing UWF-FA) - an active area of technological development (Tan TE et al., 2023, PMID 37359003).
• AI-assisted UWF image analysis: deep learning algorithms are being developed and validated for automated grading of diabetic retinopathy severity, detection of peripheral lesions, and screening triage directly from UWF colour photographs, supporting large-scale screening programs.
• Growing evidence base establishing peripheral lesions on UWF imaging as independent predictors of disease progression in diabetic retinopathy, reinforcing incorporation of UWF imaging into risk stratification (rather than purely descriptive use) - reviewed extensively in Liu Z et al., 2025 (PMID 41113340) on precision diagnostics for high-risk proliferative diabetic retinopathy.
• Increasing integration of UWF imaging into multimodal retinal inflammation/uveitis imaging protocols alongside OCT and autofluorescence for comprehensive peripheral disease assessment (Uddin MJ, 2025, PMID 40712880).
• Expanding pediatric screening applications and improved portable/handheld UWF systems, addressing gaps in ROP and pediatric retinal disease screening access (Chew LA et al., 2025, PMID 39998615).

8. Exam-Focused Summary

• UWF imaging captures up to 200 degrees (vs ~30-50 degrees standard) in a single image, mostly via scanning laser ophthalmoscopy, often without pupil dilation.
• Most valuable and best-studied application: diabetic retinopathy - detecting peripheral non-perfusion and lesions that predict disease progression and refine staging.
• Also key in retinal vein occlusion, uveitic vasculitis, sickle cell retinopathy, ROP, and peripheral retinal degenerations/tumors.
• Main limitation: peripheral image distortion and artifact; complements rather than replaces clinical examination (indirect ophthalmoscopy) and standard imaging.

Key Sources

• Kanski's Clinical Ophthalmology, 10th ed., "Wide-field imaging" section, p. 582; sickle cell retinopathy and retinal vasculitis sections
• EyeWiki - Wide Field Retinal Imaging Systems
• Ultra-widefield retinal imaging: an update on recent advances - PMC (PMC6971964)
• Liu Z et al. "Integrative Management of High-Risk Proliferative Diabetic Retinopathy: Precision Diagnostics via Ultra-Widefield Imaging and Therapeutic Strategies." Diabetes Metab Syndr Obes. 2025 (PMID 41113340)
• Tan TE et al. "Clinical utility of ultra-widefield fluorescein angiography and optical coherence tomography angiography for retinal vein occlusions." Front Med. 2023 (PMID 37359003)
• Uddin MJ. "Advances in imaging retinal inflammation." Exp Eye Res. 2025 (PMID 40712880)

Fundus Autofluorescence (FAF) - Short Note

Principle

What It Shows

• Hyperautofluorescence = increased signal, indicating RPE stress with excess lipofuscin accumulation (RPE dysfunction).
• Hypoautofluorescence = decreased signal, indicating loss of lipofuscin/RPE cells, RPE atrophy, fibrosis, or blockage of the signal (e.g., by blood, hard exudate, dense pigment).

Clinical Applications

• Inherited retinal degenerations (e.g., Stargardt disease, retinitis pigmentosa) - diagnosis and monitoring of RPE involvement.
• Geographic atrophy (dry AMD) - hyperautofluorescent rings at the leading edge of atrophic lesions predict areas of impending RPE/photoreceptor loss; atrophic areas themselves show hypoautofluorescence.
• Reveals more extensive macular disease than visible clinically (e.g., in MEWDS - multiple evanescent white dot syndrome).
• Useful in central serous chorioretinopathy, pattern dystrophies, drug toxicity (e.g., hydroxychloroquine retinopathy), and monitoring of RPE detachments/tears.

Limitations

• Susceptible to artifact from media opacities (cataract, vitreous haemorrhage).
• Signal can be affected by macular pigment (xanthophyll) absorption centrally, and by natural lens autofluorescence in phakic eyes.

Exam Tip